Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

ries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:5/26/2015)... , May 26, 2015 ... business solutions, today announced the results of an ... perform day-to-day activities. 759 therapists, practice owners and ... a widespread industry need for technology and services ... to the survey findings, Clinicient published a free ...
(Date:5/26/2015)... , May 26, 2015  PAREXEL International Corporation (NASDAQ: ... presenting at the Goldman Sachs Healthcare Conference in Palos ... Chief Executive Officer, will be making a presentation on ... on Tuesday, June 9, 2015. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:5/26/2015)... TAMPA, Fla. , May 26, 2015 /PRNewswire/ ... wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. ("PVMS"), ... today that effective immediately Mr. Matt Capps ... Senior Public Relations Consultant to the Company,s Community ... financial position in Advanzeon.  This engagement provides for ...
Breaking Medicine Technology:Survey: Half of Physical Therapists Underbill For Their Services 2PAREXEL International To Present At Goldman Sachs Healthcare Conference 2Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 2Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 3Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 4
... , , NEW YORK, Dec. 21 ... a leading provider of pre-disease adult stem cell collection, processing ... to VSEL(TM) technology that uses very small embryonic-like stem cells ... two oral presentations at the prestigious American Society of Hematology ...
... , PRINCETON, N.J., Dec. 21 Soligenix, ... formerly known as DOR BioPharma, Inc., a late-stage biotechnology ... 1/2 clinical trial evaluating SGX201, a time-release formulation of ... acute radiation enteritis. This study will be supported in ...
Cached Medicine Technology:The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 2The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 3The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 4The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 5Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 2Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 3Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 4Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 5Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 6
(Date:5/27/2015)... One of America's most cherished actors, James Earl Jones, ... takes a look at the topic of atrial fibrillation. ... heart rhythm. Those who suffer from atrial fibrillation have ... quickly. , This new segment will take a look ... inform viewers about possible signs that commonly indicate the ...
(Date:5/27/2015)... 2015 Hands On HealthCare Massage ... offering Eco-fin Hand Treatments to spa party guests, effective ... wax alternative. It is a healthy, nourishing hand/foot treatment ... and pure essential oils. No petroleum, artificial dyes, or ... treatments for our mobile spa party services ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 The Advanced Fertility ... is open for business to better serve the needs ... the Jefferson Park neighborhood on the Northwest side of the ... Appointments can be arranged by calling the Chicago office at ... the Advanced Fertility Center of Chicago. The other 2 ...
(Date:5/26/2015)... 27, 2015 Local dentist Abid Paghdiwala ... restful night’s sleep. Dr. Paghdiwala of Pearl Dental Arts ... (AADSM) member. AADSM is the leading national organization for ... oral appliance therapy, an effective alternative treatment to the ... , “Sleeping with a CPAP machine, which includes ...
(Date:5/26/2015)... OAK BROOK, Ill. (PRWEB) May 26, 2015 ... may be an early marker of specific types of ... of a new study published in the journal Radiology. ... Federica Agosta, M.D., Ph.D., co-author of the study conducted ... in Milan, Italy. “However, white matter damage has a ...
Breaking Medicine News(10 mins):Health News:Long Island's Massage and Spa Of Commack Announces A Change To Their Spa Party Menu Of Services 2Health News:Long Island's Massage and Spa Of Commack Announces A Change To Their Spa Party Menu Of Services 3Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Philadelphia sleep apnea dentist now offers oral appliances to treat snoring 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3
... and Emerging Targeted Therapies Such As AstraZeneca,s Iressa and ... 2013, According to a New Report from Decision Resources ... the world,s leading research and advisory firms focusing on ... cancer drug market in China will more than double ...
... oximetry data may help identify difficult to diagnose disease ... Somanetics Corporation (Nasdaq: SMTS ) announced today ... and presentations at the Pediatric Academic Societies (PAS) annual ... The studies focused on early applications of the technology ...
... -- Style maven and trend setter Kim Kardashian ... "Fit In Your Jeans By Friday." Produced and distributed by ... to have you crunching, lunging and wriggling into the latest ... 9th, 2009."Women need a realistic body image. My program is ...
... N.C., May 6 RIEMSER ... implant and wound healing products, has announced an upcoming ... on Friday, June 5th from 8:00 am to 1:30 ... preservation, information on bone grafting materials and methods, and ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 ... Chief Executive Officer of Endo, will review the company,s products ... be accessed from Endo,s website at www.endo.com ...
... NEW YORK, May 6 CorMatrix Cardiovascular, Inc., ... unique extracellular matrix (ECM(TM)) biomaterial devices that harness ... tissue, today announced that Robert G. Matheny, M.D., ... the company,s ECM Technology(TM) at the 2009 Advanced ...
Cached Medicine News:Health News:Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 3Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 4Health News:Kim Kardashian Says Real Women Keep Their Curves With 'Fit In Your Jeans By Friday' 2Health News:RIEMSER Announces Upcoming Scottsdale Bone Grafting Workshop 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y. 2
Long handle occluders are approximately 9 inches long....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: